ARTICLE: https://oncologytube.com/til-therapy-breakthroughs-oncologists/
Join Dr. Allison Betof Warner, Director of the Melanoma Program at Stanford, as she unveils groundbreaking advances in TIL (Tumor-Infiltrating Lymphocyte) therapy for melanoma. Discover how lifileucel achieves a 96% 10-year survival rate for responders and how engineered OBX-115 delivers a 67% response rate in PD-1 refractory cases. Learn about the TILVANCE-301 trial, safety innovations, and the future of oncology beyond melanoma. Recorded October 2025.
Timestamps
[00:00] - Teaser: 96% Survival & 67% Response in Melanoma
[00:18] - Introduction: Dr. Allison Betof Warner at Stanford
[01:34] - Question: How did Lucal help patients with PD-1 resistant melanoma?
[02:35] - Question: In the Tilvince 301 trial, how might measuring overall response and progression-free survival show if lifileucel works better?
[02:49] - Explanation: TILVANCE-301 trial details and frontline potential
[04:23] - Question: What is OBX 115, and how could it make TIL therapy safer?
[04:36] - Explanation: OBX-115 with regulatable mbIL-15 and 67% response rate
[05:56] - Question: How might improving TIL therapy change treatment options for patients?
[06:04] - Explanation: Expanding TIL to other cancers and one-time treatment benefits
Video interviews to be posted from this event at these websites...
https://oncologytube.com/tag/moasc/
https://moasc.org/
https://anco.org/
About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.
Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter: https://twitter.com/OncologyTube
LinkedIn: https://www.linkedin.com/company/oncologytube-com
Facebook: https://www.facebook.com/OncologyTube
Instagram: https://www.instagram.com/oncologytube
YouTube: https://www.youtube.com/c/OncologyTube
Connect with Us:
Share your thoughts in the comments! Join the discussion.
Join Dr. Allison Betof Warner, Director of the Melanoma Program at Stanford, as she unveils groundbreaking advances in TIL (Tumor-Infiltrating Lymphocyte) therapy for melanoma. Discover how lifileucel achieves a 96% 10-year survival rate for responders and how engineered OBX-115 delivers a 67% response rate in PD-1 refractory cases. Learn about the TILVANCE-301 trial, safety innovations, and the future of oncology beyond melanoma. Recorded October 2025.
Timestamps
[00:00] - Teaser: 96% Survival & 67% Response in Melanoma
[00:18] - Introduction: Dr. Allison Betof Warner at Stanford
[01:34] - Question: How did Lucal help patients with PD-1 resistant melanoma?
[02:35] - Question: In the Tilvince 301 trial, how might measuring overall response and progression-free survival show if lifileucel works better?
[02:49] - Explanation: TILVANCE-301 trial details and frontline potential
[04:23] - Question: What is OBX 115, and how could it make TIL therapy safer?
[04:36] - Explanation: OBX-115 with regulatable mbIL-15 and 67% response rate
[05:56] - Question: How might improving TIL therapy change treatment options for patients?
[06:04] - Explanation: Expanding TIL to other cancers and one-time treatment benefits
Video interviews to be posted from this event at these websites...
https://oncologytube.com/tag/moasc/
https://moasc.org/
https://anco.org/
About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.
Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter: https://twitter.com/OncologyTube
LinkedIn: https://www.linkedin.com/company/oncologytube-com
Facebook: https://www.facebook.com/OncologyTube
Instagram: https://www.instagram.com/oncologytube
YouTube: https://www.youtube.com/c/OncologyTube
Connect with Us:
Share your thoughts in the comments! Join the discussion.
- Categoria
- Oncology
Commenta per primo questo video.









